Breaking News

Recipharm Begins Manufacture of Chloroquine Phosphate

Secures supply of the API chloroquine phosphate for Klorokinfosf drug; ramps up production in the event that demand increases for potential COVID-19 therapy

By: Contract Pharma

Contract Pharma Staff

Recipharm, a contract development and manufacturing organization, has secured supply of the active pharmaceutical ingredient (API) chloroquine phosphate for its drug Klorokinfosf at RPH Pharma and has begun manufacturing the product. Chloroquine phosphate may be used as a potential therapy for COVID-19 patients. While chloroquine products are not currently indicated for treatment or prevention of COVID-19 and must only be prescribed according to current guidelines, a large number of clinical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters